This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Danilenko, D. M. Search for Related Content PubMed PubMed Citation Articles by Danilenko, D. M. Social Bookmarking                         What's this?

Preclinical and Early Clinical Development of Keratinocyte Growth Factor, an Epithelial- Specific Tissue Growth Factor

Department of Pathology, Amgen, Inc., Thousand Oaks, California 91320-1789, ddanilen{at}amgen.com.

Keratinocyte growth factor (KGF) is a 28-kDa heparin-binding member of the fibroblast growth factor (FGF) family (alternative designation = FGF-7) that specifically binds to the KGF receptor, a splice variant of FGF receptor 2, which is expressed only in epithelial tissues. KGF has been identified as an important paracrine mediator of proliferation and differentiation in a wide variety of epithelial cells, including hepatocytes and gastrointestinal epithelial cells, type II pneumocytes, transitional urothelial cells, and keratinocytes in all stratified squamous epithelia. Systemic administration of recombinant human KGF (rHuKGF) provides significant cytoprotection to epithelial tissues in a number of different animal models of epithelial/mucosal damage, including models of injury to the gastrointestinal tract, lung, urinary bladder, and hair follicles. The results obtained with these preclinical models prompted an investigation of the use of rHuKGF as a cytoprotective agent against radiation- and/or chemotherapy-induced oral and gastrointestinal mucositis. Several dose- and time-variable studies were conducted in normal rhesus macaques to determine the lowest dose and shortest duration of rHuKGF administration required to induce oral mucosal proliferation without other significant systemic effects. Numerous studies were also conducted in murine models of chemotherapy-induced mucositis to fine-tune the dosing schedule. These studies showed that 2-3 days of rHuKGF administration were sufficient to induce significant oral mucosal proliferation and to protect against gastrointestinal mucositis when administered prior to the initiation of chemotherapy. The results from these models were used to design a phase I study in normal human volunteers to evaluate the safety of rHuKGF and its ability to induce oral mucosal proliferation. rHuKGF was well tolerated and induced a significant increase in markers of oral mucosal proliferation following 3 days of administration at the highest doses. Phase I/II studies to evaluate the safety and efficacy of rHuKGF in the prevention of chemotherapy-induced mucositis are currently in progress.

Key Words: Chemotherapy • cytoprotection • intestine • mucositis • oral mucosa • proliferation

Toxicologic Pathology, Vol. 27, No. 1, 64-71 (1999)
DOI: 10.1177/019262339902700113


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Zhao, K.-A. Kim, J. De Vera, S. Palencia, M. Wagle, and A. Abo R-Spondin1 protects mice from chemotherapy or radiation-induced oral mucositis through the canonical Wnt/{beta}-catenin pathway PNAS, February 17, 2009; 106(7): 2331 - 2336. [Abstract] [Full Text] [PDF]

				O. Alpdogan, V. M. Hubbard, O. M. Smith, N. Patel, S. Lu, G. L. Goldberg, D. H. Gray, J. Feinman, A. A. Kochman, J. M. Eng, et al. Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration Blood, March 15, 2006; 107(6): 2453 - 2460. [Abstract] [Full Text] [PDF]

				M. L Radtke and J. M Kolesar Palifermin (KepivanceTM) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support Journal of Oncology Pharmacy Practice, September 1, 2005; 11(3): 121 - 125. [Abstract] [PDF]

				T. O. Carpenter, B. K. Ellis, K. L. Insogna, W. M. Philbrick, J. Sterpka, and R. Shimkets Fibroblast Growth Factor 7: An Inhibitor of Phosphate Transport Derived from Oncogenic Osteomalacia-Causing Tumors J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1012 - 1020. [Abstract] [Full Text] [PDF]

				E. Alvarez, E. G. Fey, P. Valax, Z. Yim, J. D. Peterson, M. Mesri, M. Jeffers, M. Dindinger, N. Twomlow, A. Ghatpande, et al. Preclinical Characterization of CG53135 (FGF-20) in Radiation and Concomitant Chemotherapy/Radiation-induced Oral Mucositis Clin. Cancer Res., August 1, 2003; 9(9): 3454 - 3461. [Abstract] [Full Text] [PDF]

				S. Braun, C. Hanselmann, M. G. Gassmann, U. auf dem Keller, C. Born-Berclaz, K. Chan, Y. W. Kan, and S. Werner Nrf2 Transcription Factor, a Novel Target of Keratinocyte Growth Factor Action Which Regulates Gene Expression and Inflammation in the Healing Skin Wound Mol. Cell. Biol., August 1, 2002; 22(15): 5492 - 5505. [Abstract] [Full Text] [PDF]

				S. Bagai, E. Rubio, J.-F. Cheng, R. Sweet, R. Thomas, E. Fuchs, R. Grady, M. Mitchell, and J. A. Bassuk Fibroblast Growth Factor-10 Is a Mitogen for Urothelial Cells J. Biol. Chem., June 21, 2002; 277(26): 23828 - 23837. [Abstract] [Full Text] [PDF]

				L. B. Ware and M. A. Matthay Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair Am J Physiol Lung Cell Mol Physiol, May 1, 2002; 282(5): L924 - L940. [Abstract] [Full Text] [PDF]

				L. S. PRINCE, P. H. KARP, T. O. MONINGER, and M. J. WELSH KGF alters gene expression in human airway epithelia: potential regulation of the inflammatory response Physiol Genomics, July 17, 2001; 6(2): 81 - 89. [Abstract] [Full Text] [PDF]

				M. Jeffers, R. Shimkets, S. Prayaga, F. Boldog, M. Yang, C. Burgess, E. Fernandes, B. Rittman, J. Shimkets, W. J. LaRochelle, et al. Identification of a Novel Human Fibroblast Growth Factor and Characterization of Its Role in Oncogenesis Cancer Res., April 1, 2001; 61(7): 3131 - 3138. [Abstract] [Full Text]

				A. Panoskaltsis-Mortari, P. A. Taylor, J. S. Rubin, A. Uren, L. A. Welniak, W. J. Murphy, C. L. Farrell, D. L. Lacey, and B. R. Blazar Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury Blood, December 15, 2000; 96(13): 4350 - 4356. [Abstract] [Full Text] [PDF]

				S. YANG, A. PANOSKALTSIS-MORTARI, D. H. INGBAR, S. MATALON, S. ZHU, E. R. RESNIK, C. L. FARRELL, D. L. LACEY, B. R. BLAZAR, and I. Y. HADDAD Cyclophosphamide Prevents Systemic Keratinocyte Growth Factor-induced Up-Regulation of Surfactant Protein A after Allogeneic Transplant in Mice Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1884 - 1890. [Abstract] [Full Text]